Ventricular Arrhythmias and Sudden Cardiac Death Management

Ventricular arrhythmias, principally sustained ventricular tachycardia and ventricular fibrillation, represent a major cause of morbidity and mortality worldwide. Sudden cardiac death accounts for up to half of all cardiovascular fatalities, frequently arising in the context of ischaemic heart disease, cardiomyopathies and inherited channelopathies. Risk stratification combines clinical assessment, imaging, electrophysiological testing and circulating biomarkers to identify individuals at highest risk and guide preventive therapies. Pharmacotherapy with antiarrhythmic agents and beta-blockers remains a cornerstone of medical management, while device therapy—chiefly implantable cardioverter-defibrillators—provides proven protection against lethal arrhythmias. Catheter ablation has emerged as an adjunct to suppress recurrent ventricular tachycardia, particularly in scar-related substrate. In patients with ischaemic cardiomyopathy, timely revascularisation before device implantation may further reduce arrhythmic events. Despite advances, risk prediction remains imperfect, prompting investigation into novel molecular markers, personalised screening protocols and refined electrophysiological approaches to enhance early detection and intervention.

Research from Nature Portfolio

A large multicentre registry analysed outcomes in patients with syncope and inducible ventricular arrhythmia undergoing defibrillator implantation. Those with syncope plus inducible arrhythmias exhibited lower one-year mortality and fewer major adverse cardiovascular events than patients receiving secondary prevention devices. Baseline profiles revealed differences in cardiomyopathy subtypes, with higher rates of hypertrophic cardiomyopathy and channelopathies among syncope patients. Adverse event rates following implantation were comparable regardless of syncope history, underscoring the prognostic value of inducible arrhythmias in guiding device implantation irrespective of presenting symptoms.

Ventricular Arrhythmias and Sudden Cardiac Death Management publication trend

The graph below shows the total number of articles in ventricular arrhythmias and sudden cardiac death management across all publications each year (not limited to Nature Index journals).

Technical terms

Ventricular tachycardia (VT): A rapid heart rhythm originating in the ventricles, which can degenerate into ventricular fibrillation if sustained.

Ventricular fibrillation (VF): A chaotic ventricular rhythm resulting in ineffective cardiac output and, if untreated, sudden cardiac death.

Implantable cardioverter-defibrillator (ICD): An internal device that detects and terminates life-threatening ventricular arrhythmias via electrical shocks.

N-terminal pro-B-type natriuretic peptide (NT-proBNP): A circulating peptide released in response to myocardial wall stress, used as a biomarker for heart failure and arrhythmic risk.

Programmed electrical stimulation (PES): An electrophysiological procedure that induces arrhythmias under controlled conditions to assess susceptibility and guide therapy.

References

1. Cardiac defibrillator implantation in patients with syncope and inducible ventricular arrhythmia: insights from the German Device Registry. Scientific Reports (2023).
2. N‐terminal pro‐B‐type natriuretic peptide for prediction of ventricular arrhythmias: Data from the SMASH study. Clinical Cardiology (2023).
3. Current Trends in Biohumoral Screening for the Risk of Sudden Cardiac Death: A Systematic Review. Medicina (2024).